Hepatitis C patients who refused treatment to wait for more effective drugs may overload the system as they seek new medications such as boceprevir and telaprevir and cause shortages and ethical issues for providers, say researchers from the University of Chicago. The report, published in the journal Hepatology, suggested a needs-based plan giving the sickest HCV patients first access to the drugs with the rest prioritized based on disease progression, beginning with those who have cirrhosis.

Related Summaries